BioMarin Pharmaceutical (BMRN) : Zbi Services L.l.c. added new position in BioMarin Pharmaceutical during the most recent quarter end. The investment management firm now holds 94,500 shares of BioMarin Pharmaceutical which is valued at $8,735,580 , the company said in a statement filed on Aug 15, 2016 with the SEC.BioMarin Pharmaceutical makes up approximately 2.07% of Zbi Services L.l.c.’s portfolio.
Other Hedge Funds, Including , Arrowstreet Capital Limited Partnership sold out all of its stake in BMRN during the most recent quarter. The investment firm sold 341,349 shares of BMRN which is valued $31,554,302.Raymond James Financial Services Advisors boosted its stake in BMRN in the latest quarter, The investment management firm added 7,096 additional shares and now holds a total of 12,010 shares of BioMarin Pharmaceutical which is valued at $1,110,204. BioMarin Pharmaceutical makes up approx 0.01% of Raymond James Financial Services Advisors’s portfolio.Tiaa Cref Investment Management reduced its stake in BMRN by selling 149,568 shares or 9.68% in the most recent quarter. The Hedge Fund company now holds 1,395,816 shares of BMRN which is valued at $129,029,231. BioMarin Pharmaceutical makes up approx 0.09% of Tiaa Cref Investment Management’s portfolio. Secor Capital Advisors Lp sold out all of its stake in BMRN during the most recent quarter. The investment firm sold 7,168 shares of BMRN which is valued $659,528.
BioMarin Pharmaceutical opened for trading at $93.7 and hit $95.49 on the upside on Thursday, eventually ending the session at $95.19, with a gain of 1.38% or 1.3 points. The heightened volatility saw the trading volume jump to 10,12,496 shares. Company has a market cap of $15,560 M.
On the company’s financial health, BioMarin Pharmaceutical reported $-2.61 EPS for the quarter, missing the analyst consensus estimate by $ -2.52 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.09. The company had revenue of $300.10 million for the quarter, compared to analysts expectations of $279.05 million. The company’s revenue was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.51 EPS.
Many Wall Street Analysts have commented on BioMarin Pharmaceutical. Company shares were Reiterated by Stifel on Aug 5, 2016 to “Buy”, Firm has raised the Price Target to $ 113 from a previous price target of $107 .Company shares were Reiterated by Piper Jaffray on Aug 5, 2016 to “Overweight”, Firm has raised the Price Target to $ 120 from a previous price target of $107 .
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).